Thursday, June 11, 2026
🇺🇸 FDA

pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)

MSD Merck Sharp

Merck Sharp and Dohme

MSD Merck Sharp clinical programs — 84 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
WERFTESTRASSE 4, Lucerne, 6005, ch HQ
61 Employees
EMA registrant Type
Company details
Status
Public
HQ
WERFTESTRASSE 4, Lucerne, 6005, ch
Employees
61
Programs
217
Drugs
180
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

MSD Merck Sharp projects

84 ClinicalTrials.gov programs sponsored by MSD Merck Sharp.

MSD Merck Sharp has 84 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

84 programs

Clinical programs

Page 1 of 2

  1. Bavencio 20 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Solid Tumors

    phase 3 small molecule active

    1 trial

  2. MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  3. MK-0616, Placebo to MK-0616

    Merck Sharp and Dohme

    ​Heterozygous Familial Hypercholesterolemia​ in pediatric patients

    phase 3 small molecule active

    1 trial

  4. MK-0616, Placebo to MK-0616 - Tablet

    Merck Sharp and Dohme

    ASCVD - Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  5. MK-0616-013

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  6. MK-0616-018

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  7. MK-0616-037

    Merck Sharp and Dohme

    Hyperlipidemia

    phase 3 small molecule active

    1 trial

  8. MK-1022-016

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  9. MK-1026-011

    Merck Sharp and Dohme

    Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  10. MK-1026-011

    Merck Sharp and Dohme

    Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  11. MK-1084-004

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  12. MK-1084-007

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 3 small molecule active

    1 trial

  13. MK-1084-012

    Merck Sharp and Dohme

    KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  14. MK-1084-013

    Merck Sharp and Dohme

    Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC

    phase 3 small molecule active

    1 trial

  15. MK-1242-043

    Merck Sharp and Dohme

    Heart Failure due to Systemic Left Ventricular Systolic Dysfunction

    phase 3 small molecule active

    1 trial

  16. MK-2140-010

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  17. MK-2400-001

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  18. MK-2870-005

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  19. MK-2870-007

    Merck Sharp and Dohme

    Metastatic non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  20. MK-2870-009

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  21. MK-2870-010

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  22. MK-2870-011

    Merck Sharp and Dohme

    Locally recurrent unresectable or metastatic TNBC with tumors expressing PD-L1 at the cut-off of CPS <10

    phase 3 small molecule active

    1 trial

  23. MK-2870-012

    Merck Sharp and Dohme

    Triple negative breast cancer.

    phase 3 small molecule active

    1 trial

  24. MK-2870-015

    Merck Sharp and Dohme

    advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

    phase 3 small molecule active

    1 trial

  25. MK-2870-019

    Merck Sharp and Dohme

    Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2])

    phase 3 small molecule active

    1 trial

  26. MK-2870-020

    Merck Sharp and Dohme

    Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.

    phase 3 small molecule active

    1 trial

  27. MK-2870-021

    Merck Sharp and Dohme

    Ovarian cancer

    phase 3 small molecule active

    1 trial

  28. MK-2870-022

    Merck Sharp and Dohme

    Ovarian cancer recurrent

    phase 3 small molecule active

    1 trial

  29. MK-2870-023

    Merck Sharp and Dohme

    Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  30. MK-2870-031

    Merck Sharp and Dohme

    Locally advanced/metastatic urothelial carcinoma

    phase 3 small molecule active

    1 trial

  31. MK-2870-032

    Merck Sharp and Dohme

    Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer

    phase 3 small molecule active

    1 trial

  32. MK-2870-033

    Merck Sharp and Dohme

    pMMR endometrial carcinoma

    phase 3 small molecule active

    1 trial

  33. MK-2870-036

    Merck Sharp and Dohme

    Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1

    phase 3 small molecule active

    1 trial

  34. MK-3475-091

    Merck Sharp and Dohme

    Stage IB (T ≥ 4 cm), II and IIIA NSCLC

    phase 3 small molecule active

    1 trial

  35. MK-3475-426

    Merck Sharp and Dohme

    Metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  36. MK-3475-585

    Merck Sharp and Dohme

    Gastric and gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  37. MK-3475-811

    Merck Sharp and Dohme

    Gastric or gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  38. MK-3475-866

    Merck Sharp and Dohme

    Cis-eligible Muscle-invasive bladder cancer.

    phase 3 small molecule active

    1 trial

  39. MK-3475-905

    Merck Sharp and Dohme

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  40. MK-3475-966

    Merck Sharp and Dohme

    Biliary Tract Carcinoma

    phase 3 small molecule active

    1 trial

  41. MK-3475-991

    Merck Sharp and Dohme

    Metastatic hormone sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  42. MK-3475-A18

    Merck Sharp and Dohme

    Locally Advanced Cervical Cancer

    phase 3 small molecule active

    1 trial

  43. MK-3475-A86

    Merck Sharp and Dohme

    Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial

  44. MK-3475-C93

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  45. MK-3475A-F84

    Merck Sharp and Dohme

    Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS ≥50%

    phase 3 small molecule active

    1 trial

  46. MK-3543-006

    Merck Sharp and Dohme

    Essential Thrombocythemia patients who have an inadequate response to or are intolerant of hydroxyurea

    phase 3 small molecule active

    1 trial

  47. MK-3543-007

    Merck Sharp and Dohme

    Essential thrombocythemia

    phase 3 small molecule active

    1 trial

  48. MK-3543-017

    Merck Sharp and Dohme

    Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does MSD Merck Sharp have?

84 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.